id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2095-0005,FDA,FDA-2022-E-2095,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2024-02-05T05:00:00Z,2024,2,2024-02-05T05:00:00Z,,2024-02-05T19:16:44Z,,0,0,09000064863e5aba